# CD34+ Stem Cell Infusion to Augment Graft Function

> **NCT01856582** · PHASE2 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 23 (actual)

## Conditions studied

- Waning Donor Chimerism
- Waning Immune Function
- Primary Immunodeficiency Disease(s)
- Bone Marrow Failure

## Interventions

- **BIOLOGICAL:** CD34+

## Key facts

- **NCT ID:** NCT01856582
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2018-08-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** CliniMACS CD34 Reagent System was FDA approved for clinical use; therefore, patients were treated clinically.
- **Last updated:** 2019-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856582, "CD34+ Stem Cell Infusion to Augment Graft Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01856582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*